|

Impact of Chemotherapy Dose Reductions on Survival Outcomes Among Older NSCLC Patients Without Actionable Mutations

RECRUITINGSponsored by University of Malaya
Actively Recruiting
SponsorUniversity of Malaya
Started2026-01-01
Est. completion2026-12-31
Eligibility
Age65 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07369596

Summary

Evidence suggests that appropriately selected older adults can tolerate standard-dose chemotherapy and achieve survival outcomes comparable to younger patients. However, older adults are usually under-represented in clinical trials and often receive reduced doses of chemotherapy due to concerns regarding age-related frailty, polypharmacy, and toxicity. This study seeks to evaluate chemotherapy dosing patterns and associated survival outcomes in older patients.

Eligibility

Age: 65 Years+Healthy volunteers accepted
Inclusion Criteria:

* Age ≥65 years
* Histologically confirmed stage IV NSCLC
* Negative for EGFR mutation, ALK rearrangement, and ROS1 fusion
* Treated with at least ONE cycle of first-line chemotherapy

Exclusion Criteria:

* Patients who received targeted therapy or immunotherapy as monotherapy in the first-line setting
* Incomplete survival data

Conditions2

Lung CancerNon-Small Cell Lung Carcinoma (NSCLC)

Browse More Trials

Lung Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.